Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience.
Betacoronavirus
COVID-19
Change Management
Communicable Disease Control
/ methods
Coronavirus Infections
/ epidemiology
Humans
Inflammatory Bowel Diseases
/ epidemiology
Italy
/ epidemiology
Pandemics
/ prevention & control
Patient Care Management
/ organization & administration
Patient Education as Topic
Pneumonia, Viral
/ epidemiology
Quality Assurance, Health Care
/ methods
Risk Reduction Behavior
SARS-CoV-2
COVID-19
Coronavirus
inflammatory bowel disease
pandemic
quality of care
Journal
Journal of Crohn's & colitis
ISSN: 1876-4479
Titre abrégé: J Crohns Colitis
Pays: England
ID NLM: 101318676
Informations de publication
Date de publication:
16 Sep 2020
16 Sep 2020
Historique:
pubmed:
27
3
2020
medline:
23
9
2020
entrez:
27
3
2020
Statut:
ppublish
Résumé
The outbreak of the COVID-19 caused by coronavirus SARS-CoV2, is rapidly spreading worldwide. This is the first pandemic caused by a coronavirus in history. More than 150 000 confirmed cases worldwide are reported involving the SARS-CoV2, with more than 5000 COVID-19-related deaths on March 14, 2020. Fever, chills, cough, shortness of breath, generalised myalgia, malaise, drowsiness, diarrhoea, confusion, dyspnoea, and bilateral interstitial pneumonia are the common symptoms. No therapies are available, and the only way to contain the virus spread is to regularly and thoroughly clean one's hands with an alcohol-based hand rub or wash them with soap and water, to maintain at least 1 m [3 feet] distance from anyone who is coughing or sneezing, to avoid touching eyes, nose, and mouth, and to stay home if one feels unwell. No data are available on the risk of COVID-19 and outcomes in inflammatory bowel disease [IBD] patients. Outbreak restrictions can impact on the IBD care. We aim to give a viewpoint on how operationally to manage IBD patients and ensure quality of care in the current pandemic era.
Identifiants
pubmed: 32211765
pii: 5811431
doi: 10.1093/ecco-jcc/jjaa058
pmc: PMC7184487
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1330-1333Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2020 Feb 29;395(10225):683-684
pubmed: 32122468
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Feb 06;43(0):E005
pubmed: 32026671
Lancet Infect Dis. 2020 Apr;20(4):425-434
pubmed: 32105637
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2012-2019
pubmed: 32141570
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
J Crohns Colitis. 2020 Sep 7;14(8):1037-1048
pubmed: 32032423
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
Int J Infect Dis. 2020 Apr;93:264-267
pubmed: 32114193
Lancet Gastroenterol Hepatol. 2020 May;5(5):425-427
pubmed: 32171057
J Autoimmun. 2020 May;109:102434
pubmed: 32143990
Signal Transduct Target Ther. 2020 Feb 21;5(1):18
pubmed: 32296012
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004